RPN2 and cancer: A recent study by Kimi Honma et al reported that RPN2 silencing and downregulation makes cancer cells hypersensitive in response to docetaxel a chemotherapeutic drug, proposing it as a target for RNA interference–based therapeutics against drug resistance [42].